Clearmind Medicine Inc. has filed a Japanese patent application for its innovative non-hallucinogenic molecule MEAI, aimed at treating depression. This strengthens its global intellectual property portfolio and targets a safer alternative to traditional antidepressants and psychedelic therapies. With depression being a major global health issue, Clearmind is expanding its research into related mental and metabolic disorders. The move positions Clearmind strongly in the growing mental health treatment market, especially in Japan where depression rates are high due to societal stress factors.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
Klarna benefits from maturing financing cohorts, low-cost deposit funding, and prudent risk management, leading to increased transaction margins and net interest income. This supports their growth strategy, reflected in accelerating gross merchandise...
G50 Corp announced that Phase 2 metallurgical tests at its Golconda project in Arizona show low-cost processing could double gallium grades while also producing gold and silver. This breakthrough reduces risks in gallium extraction, a critical minera...
